Literature DB >> 29300962

Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Nicolas J Schlienz1, Edward J Cone1, Evan S Herrmann2, Natalie A Lembeck1, John M Mitchell3, George E Bigelow1, Ronald Flegel4, Charles P LoDico4, Eugene D Hayes4, Ryan Vandrey1.   

Abstract

Understanding the urine excretion profile for Δ9-tetrahydrocannabinol (THC) metabolites is important for accurate detection and interpretation of toxicological testing for cannabis use. Prior literature has primarily evaluated the urinary pharmacokinetics of the non-psychoactive THC metabolite 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) following smoked cannabis administration. The present study examined the urine THCCOOH excretion profile following oral cannabis administration in 18 healthy adults. Following ingestion of a cannabis-containing brownie with 10, 25 or 50 mg of THC (N = 6 per dose), urine specimens were collected on a closed residential research unit for 6 days, followed by three outpatient visits on Days 7-9. Average maximum concentrations (Cmax) of THCCOOH were 107, 335 and 713 ng/mL, and average times to maximum concentration (Tmax) were 8, 6 and 9 h for the 10, 25 and 50 mg THC doses, respectively. Detection windows to first positive and last positive varied as a function of dose; higher doses had shorter time to first positive and longer time to last positive. Considerable inter-subject variability was observed on study outcomes. Gas chromatography/mass spectrometry (GC/MS; 15 ng/mL cutoff) was used as the criterion to assess sensitivity, specificity and agreement for THCCOOH qualitative immunoassay tests using 20, 50 and 100 ng/mL cutoffs. The 50 ng/mL cutoff displayed good sensitivity (92.5%), specificity (92.4%) and overall agreement (92.4%), whereas the 20 ng/mL cutoff demonstrated poor specificity (58.4%), and the 100 ng/mL cutoff exhibited reduced sensitivity (70.9%). Ingestion of cannabis brownies containing the 10 and 25 mg THC doses yielded THCCOOH concentrations that differed in magnitude and time course from those previously reported for the smoked route of administration of comparable doses.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29300962      PMCID: PMC5907340          DOI: 10.1093/jat/bkx102

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  24 in total

1.  Cannabis use, cognitive performance and mood in a sample of workers.

Authors:  E J K Wadsworth; S C Moss; S A Simpson; A P Smith
Journal:  J Psychopharmacol       Date:  2005-10-04       Impact factor: 4.153

2.  Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.

Authors:  M A ElSohly; H deWit; S R Wachtel; S Feng; T P Murphy
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

3.  Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana.

Authors:  M A Huestis; J M Mitchell; E J Cone
Journal:  J Anal Toxicol       Date:  1996-10       Impact factor: 3.367

4.  Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys.

Authors:  Wilson M Compton; Beth Han; Christopher M Jones; Carlos Blanco; Arthur Hughes
Journal:  Lancet Psychiatry       Date:  2016-08-31       Impact factor: 27.083

5.  Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use.

Authors:  Morris S Odell; Matthew Y Frei; Dimitri Gerostamoulos; Mark Chu; Dan I Lubman
Journal:  Forensic Sci Int       Date:  2015-01-30       Impact factor: 2.395

6.  Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results.

Authors:  Edward J Cone; George E Bigelow; Evan S Herrmann; John M Mitchell; Charles LoDico; Ronald Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2014-10-17       Impact factor: 3.367

7.  Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use.

Authors:  Dustin C Lee; Alan J Budney; Mary F Brunette; John R Hughes; Jean-Francois Etter; Catherine Stanger
Journal:  Drug Alcohol Depend       Date:  2015-08-10       Impact factor: 4.492

8.  Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans.

Authors:  Richard A Gustafson; Barry Levine; Peter R Stout; Kevin L Klette; M P George; Eric T Moolchan; Marilyn A Huestis
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

9.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

10.  Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.

Authors:  Deborah S Hasin; Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Bridget F Grant
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

View more
  6 in total

1.  Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.

Authors:  Marilyn A Huestis; Cristina Sempio; Matthew N Newmeyer; Maria Andersson; Allan J Barnes; Osama A Abulseoud; Benjamin C Blount; Jennifer Schroeder; Michael L Smith
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

2.  Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.

Authors:  Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-01-07       Impact factor: 3.367

3.  Cannabinoids from Cannabis sativa L.: A New Tool Based on HPLC-DAD-MS/MS for a Rational Use in Medicinal Chemistry.

Authors:  Michele Protti; Virginia Brighenti; Maria Rita Battaglia; Lisa Anceschi; Federica Pellati; Laura Mercolini
Journal:  ACS Med Chem Lett       Date:  2019-01-29       Impact factor: 4.345

4.  Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects.

Authors:  Alison C McDonald; Israel Gasperin Haaz; Weikai Qi; David C Crowley; Najla Guthrie; Malkanthi Evans; Dan Bosnyak
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

Review 5.  Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Authors:  Ainhoa Bilbao; Rainer Spanagel
Journal:  BMC Med       Date:  2022-08-19       Impact factor: 11.150

6.  Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults.

Authors:  Natasha E Wade; Rachel Baca; Kelly E Courtney; Connor J McCabe; M Alejandra Infante; Marilyn A Huestis; Joanna Jacobus
Journal:  J Int Neuropsychol Soc       Date:  2021-07       Impact factor: 2.892

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.